Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November
Pharming Group reported preliminary Q3 2026 revenue of $117.6 million, up 21% year-over-year and above market expectations, with net profit of $22.4 million versus $7.5 million a year ago. Joenja grew 58% to $23.8 million on U.S. patient gains plus launches in Germany and Japan, while RUCONEST returned to growth at $93.8 million (+14%), aided by seasonal channel inventory rebuild at a single U.S. specialty pharmacy.
Key figures
- Eps
- 0.032
- Revenue
- 117600000
- Guidance
- 2026 total revenue US$380 million-US$390 million (tightened from prior US$375 million-US$395 million); total operating expenses US$310.0 million-US$315.0 million
- Revenue Yoy
- 21%
- Net profit
- 22400000
- Cash position
- 190900000
- Joenja revenue
- 23800000
- Operating income
- 29900000
- Ruconest revenue
- 93800000
- Joenja revenue yoy
- 58%
- Operating income yoy
- 89%
- Ruconest revenue yoy
- 14%
- Operating cash flow q3
- 32400000
- Operating cash flow ytd
- 24700000
- Us paid patients joenja
- 136
- Phase2 spleen volume reduction
- 26.4%
- Diagnosed apds patients globally
- 1056
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.